History

How the Convatec Story Has Changed

A real turnaround story that has earned the right to be believed — but is being tested at the worst possible moment. Karim Bitar inherited a "rudderless" company in 2019 (two profit warnings the prior year, shares at half their 2016 IPO price, EQT takeover chatter) and over six years delivered six consecutive years of accelerating growth, 460 bps of adjusted operating margin expansion against punishing inflation, and the strongest pipeline in the company's 50-year history. Three shocks now concentrate in 13 months: the CMS price cut that destroyed 80% of InnovaMatrix economics (and forced a $72m impairment on a 2022 acquisition once described as transformational); Bitar's death in October 2025; and an FDA warning letter on Infusion Care complaint handling disclosed at FY25 results. Management's response so far is candid and operationally focused — but the medium-term margin promise of "mid-20s by 2026 or 2027" has quietly slipped to "closer to 24% by 2027," and a new CEO has to relaunch the InnovaMatrix franchise, fix the FDA observations, and prove the 6–8% growth upgrade in his first full year.

1. The Narrative Arc

2. What Management Emphasized — and Then Stopped Emphasizing

The chart traces the deliberate substitution of one frame with another. The early Bitar era was about an emergency framework — FISBE, "4%+ sustainable," and a transformation programme — and the language changed once the transformation worked. By 2024 management had largely stopped saying "4%+" and was using "5–7%" instead; in 2026 Mason is upgrading again to "6–8% from 2027," with the FISBE label being explicitly retired ("the new strategy") at the April 2026 Capital Markets Day. The pipeline language is the only theme that has steadily intensified over six years, which is consistent with launches genuinely flowing.

Themes that quietly went away:

• Avelle / original single-use NPWT — heavily promoted in 2020 quality discussion ("we have had quality challenges there with the whole pump system"). Disappeared. Now reframed as "it really was not ready for showtime" (Feb 2025) — replaced by ConvaVac.
• "4%+ for six semesters" — Bitar's own credibility framing in 2020. Stopped being mentioned in 2023 once it was already exceeded.
• China as a "win or lose" market — flagged in 2020 as one of two indispensable markets. By 2024 muted to "anti-corruption campaign" headwind; by 2025 to "back to growth" with no fanfare.
• Patch pumps — three years of hedging that Convatec was "very busy bunnies" without committing. By 2025 explicitly de-prioritised: "irrespective of whether we are on a patch pump or not, we will deliver high single-digit growth."

Themes that arrived in 2026 and were not there before:

• Quality / FDA / complaints-handling — 2020-25 was a story of improving quality (complaints per million down 20%); Feb 2026 reveals a warning letter and "best internal team working intensively on it."
• Reimbursement headwind as a normal operating reality — the 2026 framing of "we expect 1% per annum, we plan for it" replaced an earlier optimism about specific tailwinds (continence reimbursement uplift in 2023).

3. Risk Evolution

Two structural shifts stand out. First, the risk register shrank from 10 entries (FY22) to 8 (FY24+) — Strategy and change management was dropped once management felt the turnaround was self-sustaining, and Tax and treasury fell off the top tier. That is consistent with the "turnaround complete" message but means there is less headroom now if the pipeline stumbles. Second, Customer and markets moved from #4 to #2 — well before the FY26 InnovaMatrix shock. The board could see CMS reimbursement risk building. Innovation and regulatory simultaneously moved down (#3 → #5) as launches landed, but the FY25 FDA warning letter calls into question whether that demotion was premature.

4. How They Handled Bad News

Three real episodes test the management style.

COVID-19 (2020). Bitar described "rephasing" investments rather than cutting them; was specific about which projects (commercial expansion in China deferred; R&D and operational excellence accelerated); reduced 2021 transformation benefits from $130–150m to a tighter range and gave the math live in Q2. Honest. No re-statement of strategy.

InnovaMatrix LCD/price cut (2024–26). A multi-stage test. In Feb 2025 management quantified the headwind directly ("$50m"); when the LCD was postponed, they raised guidance promptly; in Feb 2026 they took a $72m non-cash impairment (~20% of the Triad acquisition price) without softening the language. They were less candid earlier — through 2023 and most of 2024, InnovaMatrix was framed as the high-margin "biologics" leg of FY24's record results, with limited acknowledgment of how exposed the franchise was to a single CMS rule. The 2025 stance — "we still believe InnovaMatrix is highly effective" alongside a write-down — is reasonable, but the previous bull case is gone.

FDA warning letter (Feb 2026). The first major "bad news" handled by the new CEO. Mason did not minimise it: "The FDA said it is not good enough, and we agree." He also pushed back specifically on the 5,000 leakage complaints cited in the warning by noting the FDA found no product safety issue, only administrative gaps. That is the right way to handle it but the test is execution speed.

5. Guidance Track Record

Why 7/10. The top-line promises (5–7% organic, double-digit EPS, simplification/G&A reduction) have all been hit, often with conservatism baked in. Bitar built a track record of under-promising and raising guidance — an investor's preferred profile. The two genuine credibility hits are: (a) the mid-20s margin target by 2026/27 has been quietly resolved to "closer to 24% by 2027" — the math worked at 125 bps/yr, but is being recalibrated as InnovaMatrix mix shrinks; (b) the InnovaMatrix bull case that justified the 2022 Triad acquisition is essentially gone. A score above 7 would require the new team to navigate the FDA letter and re-build InnovaMatrix without further surprises; a score below 7 would require the new 6–8% target to slip in its first year.

6. What the Story Is Now

The current story, in one paragraph. Convatec is a chronic-care medtech that turned itself around between 2019 and 2024 by narrowing its focus, doubling R&D, simplifying corporate overhead, and rebuilding a pipeline. It now generates ~22% adjusted operating margins on $2.4bn of sales, returns cash, and is heading into a bigger investment cycle (capex up materially in 2026) with a credible pipeline of 16 launches over 2022–27. The story is no longer "can the turnaround work" — it is "can the new team compound through three concentrated tests": the FDA warning, an impaired biologics franchise, and the absence of the architect of the strategy. Mason and Ryder have a head start because the operating system Bitar built is institutional, not personal; the pipeline they inherited is unusually deep; and so far they have spoken about bad news directly. But the margin walk-back and the impairment are real. The market should believe the cash flow, the pipeline cadence, and the simplification math — and discount any future promise that depends on a single reimbursement decision going Convatec's way.

title: History — Convatec Group plc (CTEC)

How the Convatec Story Has Changed

A real turnaround story that has earned the right to be believed — but is being tested at the worst possible moment. Karim Bitar inherited a "rudderless" company in 2019 (two profit warnings the prior year, shares at half their 2016 IPO price, EQT takeover chatter) and over six years delivered six consecutive years of accelerating growth, 460 bps of adjusted operating margin expansion against punishing inflation, and the strongest pipeline in the company's 50-year history. Three shocks now concentrate in 13 months: the CMS price cut that destroyed 80% of InnovaMatrix economics (and forced a $72m impairment on a 2022 acquisition once described as transformational); Bitar's death in October 2025; and an FDA warning letter on Infusion Care complaint handling disclosed at FY25 results. Management's response so far is candid and operationally focused — but the medium-term margin promise of "mid-20s by 2026 or 2027" has quietly slipped to "closer to 24% by 2027," and a new CEO has to relaunch the InnovaMatrix franchise, fix the FDA observations, and prove the 6–8% growth upgrade in his first full year.

1. The Narrative Arc

2. What Management Emphasized — and Then Stopped Emphasizing

The chart traces the deliberate substitution of one frame with another. The early Bitar era was about an emergency framework — FISBE, "4%+ sustainable," and a transformation programme — and the language changed once the transformation worked. By 2024 management had largely stopped saying "4%+" and was using "5–7%" instead; in 2026 Mason is upgrading again to "6–8% from 2027," with the FISBE label being explicitly retired ("the new strategy") at the April 2026 Capital Markets Day. The pipeline language is the only theme that has steadily intensified over six years, which is consistent with launches genuinely flowing.

Themes that quietly went away:

• Avelle / original single-use NPWT — heavily promoted in 2020 quality discussion ("we have had quality challenges there with the whole pump system"). Disappeared. Now reframed as "it really was not ready for showtime" (Feb 2025) — replaced by ConvaVac.
• "4%+ for six semesters" — Bitar's own credibility framing in 2020. Stopped being mentioned in 2023 once it was already exceeded.
• China as a "win or lose" market — flagged in 2020 as one of two indispensable markets. By 2024 muted to "anti-corruption campaign" headwind; by 2025 to "back to growth" with no fanfare.
• Patch pumps — three years of hedging that Convatec was "very busy bunnies" without committing. By 2025 explicitly de-prioritised: "irrespective of whether we are on a patch pump or not, we will deliver high single-digit growth."

Themes that arrived in 2026 and were not there before:

• Quality / FDA / complaints-handling — 2020-25 was a story of improving quality (complaints per million down 20%); Feb 2026 reveals a warning letter and "best internal team working intensively on it."
• Reimbursement headwind as a normal operating reality — the 2026 framing of "we expect 1% per annum, we plan for it" replaced an earlier optimism about specific tailwinds (continence reimbursement uplift in 2023).

3. Risk Evolution

Two structural shifts stand out. First, the risk register shrank from 10 entries (FY22) to 8 (FY24+) — Strategy and change management was dropped once management felt the turnaround was self-sustaining, and Tax and treasury fell off the top tier. That is consistent with the "turnaround complete" message but means there is less headroom now if the pipeline stumbles. Second, Customer and markets moved from #4 to #2 — well before the FY26 InnovaMatrix shock. The board could see CMS reimbursement risk building. Innovation and regulatory simultaneously moved down (#3 → #5) as launches landed, but the FY25 FDA warning letter calls into question whether that demotion was premature.

4. How They Handled Bad News

Three real episodes test the management style.

COVID-19 (2020). Bitar described "rephasing" investments rather than cutting them; was specific about which projects (commercial expansion in China deferred; R&D and operational excellence accelerated); reduced 2021 transformation benefits from $130–150m to a tighter range and gave the math live in Q2. Honest. No re-statement of strategy.

InnovaMatrix LCD/price cut (2024–26). A multi-stage test. In Feb 2025 management quantified the headwind directly ("$50m"); when the LCD was postponed, they raised guidance promptly; in Feb 2026 they took a $72m non-cash impairment (~20% of the Triad acquisition price) without softening the language. They were less candid earlier — through 2023 and most of 2024, InnovaMatrix was framed as the high-margin "biologics" leg of FY24's record results, with limited acknowledgment of how exposed the franchise was to a single CMS rule. The 2025 stance — "we still believe InnovaMatrix is highly effective" alongside a write-down — is reasonable, but the previous bull case is gone.

FDA warning letter (Feb 2026). The first major "bad news" handled by the new CEO. Mason did not minimise it: "The FDA said it is not good enough, and we agree." He also pushed back specifically on the 5,000 leakage complaints cited in the warning by noting the FDA found no product safety issue, only administrative gaps. That is the right way to handle it but the test is execution speed.

5. Guidance Track Record

Why 7/10. The top-line promises (5–7% organic, double-digit EPS, simplification/G&A reduction) have all been hit, often with conservatism baked in. Bitar built a track record of under-promising and raising guidance — an investor's preferred profile. The two genuine credibility hits are: (a) the mid-20s margin target by 2026/27 has been quietly resolved to "closer to 24% by 2027" — the math worked at 125 bps/yr, but is being recalibrated as InnovaMatrix mix shrinks; (b) the InnovaMatrix bull case that justified the 2022 Triad acquisition is essentially gone. A score above 7 would require the new team to navigate the FDA letter and re-build InnovaMatrix without further surprises; a score below 7 would require the new 6–8% target to slip in its first year.

6. What the Story Is Now

The current story, in one paragraph. Convatec is a chronic-care medtech that turned itself around between 2019 and 2024 by narrowing its focus, doubling R&D, simplifying corporate overhead, and rebuilding a pipeline. It now generates ~22% adjusted operating margins on $2.4bn of sales, returns cash, and is heading into a bigger investment cycle (capex up materially in 2026) with a credible pipeline of 16 launches over 2022–27. The story is no longer "can the turnaround work" — it is "can the new team compound through three concentrated tests": the FDA warning, an impaired biologics franchise, and the absence of the architect of the strategy. Mason and Ryder have a head start because the operating system Bitar built is institutional, not personal; the pipeline they inherited is unusually deep; and so far they have spoken about bad news directly. But the margin walk-back and the impairment are real. The market should believe the cash flow, the pipeline cadence, and the simplification math — and discount any future promise that depends on a single reimbursement decision going Convatec's way.